Unlocking the potential of
AI-driven drug discovery with quantitative data at scale
Guided by powerful AI capabilities, we are leveraging our vast high-quality data to optimize the path from discovery to transformative therapeutics.
Fully Realized Small Molecule Drug Discovery
Our approach delivers on the promise of computation to revolutionize drug discovery. Through our closed-loop wet lab discovery platform and data-rich AI, we overcome existing constraints on chemical data by systematically mapping the biochemical interactions of massive and diverse small molecule libraries to identify novel therapeutic compounds. Access to this quantitative data at scale allows us to intelligently navigate an infinitely extensible and highly diverse chemical space to efficiently design, discover and optimize small molecule therapeutics.
An Unparalleled Platform Solution
Our integrated computational platform, tNova, harnesses our novel affinity binding technology, tArray, unique resynthesis capabilities, and broad biology infrastructure.
tArray is the foundation of our discovery engine. It enables us to screen hundreds of millions of compounds in minutes and return quantitative data on each compound. Vast, high purity, and high diversity compound libraries are rapidly iterated using best-in-class chemistry to unlock chemical insights at the scale necessary to power AI-driven drug discovery.
A Unified Vision – We are a highly skilled, dedicated, and passionate team that combines specific expertise and experience in AI, synthetic chemistry, biology, automation, and nanotechnology with the bold vision to accelerate cures and advance human health.
Jacob is a distinguished inventor at the intersection of nanotechnology and synthetic chemistry. Prior to joining Terray full-time, he ran an NIH-funded lab at City of Hope, where he was an associate professor. He has more than 40 publications, 20 patents and over 11 thousand citations associated with his work. He was named one of the “Rising Stars and Young Nanoarchitects in Materials Science” by the Royal Society of Chemistry and was nominated for the Kabiller Young Investigator Award in Nanoscience and Nanomedicine. Jacob received his PhD in organometallic chemistry from CalTech where he studied with Nobel Laureate Bob Grubbs. Jacob completed his postdoctoral training at MIT and Rice University focusing on synthetic chemistry and nanotechnology, and received a BA in chemistry from Harvard University (magna cum laude).
Prior to joining Terray, Vanessa most recently served as Vice President of Biology at Rigel Pharmaceuticals and brings over 19 years of experience in small molecule drug discovery to the company. In this role, she was responsible for leading preclinical research programs from target identification to lead candidate selection as well as support of IND filings and early clinical studies. During her tenure at Rigel, she was directly involved in taking 7 drug candidates into clinical studies focused on inflammatory and rare diseases and partnering of 3 additional programs. Vanessa received her B.S. from Durham University in Molecular Biology and Biochemistry, her Ph.D. in Immunology from the University of Cambridge and completed her postdoctoral training at Oxford University’s Institute of Molecular Medicine and the University of California, San Francisco
Prior to joining Terray, Narbe was a Senior Scientist at Amgen. In this role, he was responsible for supporting all aspects of computational small molecule drug discovery, including the development of advanced quantum mechanics and machine learning methods, as well as cloud-based solutions to support high-throughput, data-driven workflows. Narbe is a thought leader in quantum mechanics, machine learning, computational chemistry, and closed-loop drug discovery. He received his B.S. in Chemical Engineering from UC Berkeley, his Ph.D. in Quantum Chemistry from UC Berkeley, and was a postdoc in Chemical Physics at Caltech.
Prior to joining Terray, Eli was at Parthenon Capital Partners, an operationally focused middle-market private equity firm where he led transactions across healthcare, software, and financial services. Prior to Parthenon, Eli worked at Irving Place Capital and Lehman Brothers. He holds an MBA from Stanford University and a BA with honors from the London School of Economics.
Prior to joining Terray, Craig was a Principal Scientist at Amgen. In this role, he was responsible for designing, testing, and implementing automation solutions across Amgen’s discovery organization. Craig has invented numerous novel technologies that encompass enhancements to both small and large molecule synthesis, purification, and screening. He was the recipient of the “Innovation of the Year” award and was the primary facilitator for out-licensing of three patents which resulted in royalty generating commercial technologies. He received his B.A. from Saint Olaf College and his Ph.D. in Chemistry from the University of Washington.
Brian Kotzin, M.D. is a board-certified rheumatologist and internist with more than three decades of experience in the fields of inflammation and immunology in academia and industry. Currently, Dr. Kotzin is currently Senior Vice President, Clinical Development at Nektar Therapeutics, Inc. Before Nektar, Dr. Kotzin served as Vice President of Global Clinical Development and Head of the Inflammation Therapeutic Area at Amgen, directing the global development efforts for Amgen’s inflammation product candidates. During his 11 years at Amgen, he also served as Vice President of Medical Sciences, which encompassed early development, biomarker development, and clinical immunology. Prior to his industry career, Dr. Kotzin served as Head of Clinical Immunology in the Department of Medicine and Director of the Autoimmunity Center of Excellence at the University of ColoradoHealth Sciences Center in Denver. Dr. Kotzin has authored more than 200 publications in medical journals, books and book chapters, and has served on the editorial boards of Arthritis and Rheumatism, The Journal of Immunology and the Journal of Clinical Investigation. He is an elected member of the American Association of Clinical Investigation, Association of American Physicians, and elected Master of the American College of Rheumatology.
Dr. Kotzin received a B.S. in mathematics from the University of Southern California and an M.D. from Stanford University School of Medicine. He completed a residency in internal medicine and a fellowship in rheumatology and medicine at Beth Israel Hospital in Boston. He was a postdoctoral fellow in the Division of Immunology and Rheumatology at Stanford University School of Medicine. He is board certified in rheumatology and internal medicine.
With her doctorate degree in Chemistry, Christine spent her early career days in academia where she developed and applied computer-assisted molecular modeling techniques while building the foundation and blueprint for the software Sybyl, later commercialized by Tripos Inc. Her research focused in the Pain, Neurosciences and Cardiovascular areas to elucidate structure-activity patterns for fentanyl, gabapentin, serotonin inhibitors among others.
She transitioned to the Pharmaceutical Industry, initially as an individual contributor and grew into an exceptional scientific and technical leader in her field. Her journey began at Parke-Davis in Ann Arbor, Michigan. Since her early days in molecular modeling and drug design, Christine has been a champion and advocate in pioneering the use of structure-based design, 3-dimensional molecular visualization and integrated platforms to analyze target families with ligand-based structure-activity data.
By systematically applying predictive approaches with medicinal chemistry desktop modeling tools, she has positively impacted therapeutics discovery as evidenced by more than 115 publications. Most recently, she led cheminformatics initiatives to transform drug discovery through artificial intelligence and machine learning techniques.
Throughout her career, she has led multiple scientific collaborations with leading academic and industrial partners. She tutored and mentored multiple group members who progressed in successful careers.
Don Payan, MD, is an experienced hands-on biotechnology physician-scientist-executive. During the past 30 years in biotechnology in the two companies he has founded (Khepri and Rigel), he has hired, organized and led highly productive multi discipline target and drug discovery and development teams in the areas of Immunology, Oncology and Muscle Wasting diseases. His teams have discovered and developed the first FDA approved oral SYK inhibitor for an autoimmune disease, as well as an additional 12 IND candidates. Moreover, he was instrumental in establishing multiple collaborations with pharmaceutical companies.
He received his BS in Physics and MD from Stanford University, and his MS in Physics from MIT. His residency in Internal Medicine and Infectious Disease fellowship were done at the Massachusetts General Hospital, Harvard Medical School. An additional fellowship in Allergy Immunology was done at the Brigham and Women’s Hospital, also at HMS. Following his training at Harvard, he joined the faculty of Medicine at the University of California San Francisco and the Howard Hughes Medical Institute. He is an author of over 200 published articles and chapters, and an inventor on over 90 issued patents. He is a member of the American Society of Clinical Investigation.